Teo Andrea York Tiang, Lim Vivian Yujing, Yang Valerie Shiwen
Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore.
Institute of Molecular and Cell Biology, A*STAR, Singapore 138673, Singapore.
Cancers (Basel). 2023 Jan 18;15(3):577. doi: 10.3390/cancers15030577.
Soft tissue sarcomas are highly aggressive malignant neoplasms of mesenchymal origin, accounting for less than 1% of adult cancers, but comprising over 20% of paediatric solid tumours. In locally advanced, unresectable, or metastatic disease, outcomes from even the first line of systemic treatment are invariably poor. MicroRNAs (miRNAs), which are short non-coding RNA molecules, target and modulate multiple dysregulated target genes and/or signalling pathways within cancer cells. Accordingly, miRNAs demonstrate great promise for their utility in diagnosing, prognosticating and improving treatment for soft tissue sarcomas. This review aims to provide an updated discussion on the known roles of specific miRNAs in the pathogenesis of sarcomas, and their potential use in prognosticating outcomes and prediction of therapeutic resistance.
软组织肉瘤是起源于间充质的高度侵袭性恶性肿瘤,占成人癌症的比例不到1%,但在儿童实体瘤中占比超过20%。在局部晚期、无法切除或转移性疾病中,即使是一线全身治疗的效果也总是很差。微小RNA(miRNA)是短的非编码RNA分子,可靶向并调节癌细胞内多个失调的靶基因和/或信号通路。因此,miRNA在软组织肉瘤的诊断、预后评估和治疗改善方面具有很大的应用前景。本综述旨在对特定miRNA在肉瘤发病机制中的已知作用及其在预后评估和治疗耐药性预测中的潜在应用进行更新讨论。